AtheroGenics, Inc.
https://www.atherogenics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AtheroGenics, Inc.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
Keeping Track: Iovance’s Amtagvi Approval Brings T Cell Therapy To Solid Tumors
Melanoma treatment Amtagvi is US FDA’s biologics center’s first novel approval of 2024.
Breaking The Pain Market’s Addiction To Opioids
The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice